Advanced search
Publication Cover
Expert Opinion on Drug Safety Volume 21, 2022 - Issue 10
Submit an article Journal homepage
2,164
Views
0
CrossRef citations to date
0
Altmetric
Original Research

Long-term safety and effectiveness of linagliptin by baseline body mass index in Japanese patients with type 2 diabetes: a 3-year post-marketing surveillance study

Daisuke Yabea Department of Diabetes, Endocrinology and Metabolism and Department of Rheumatology and Clinical Immunology, Gifu University Graduate School of Medicine, Gifu, Japan;b Yutaka Seino Distinguished Center for Diabetes Research, Kansai Electric Power Medical Research Institute, Kobe, Japan;c Division of Molecular and Metabolic Medicine, Kobe University Graduate School of Medicine, Kobe, Japan;d Center for Healthcare Information Technology, Tokai National Higher Education and Research System, Nagoya, JapanORCID Iconhttps://orcid.org/0000-0002-5334-7687View further author information
ORCID Icon,
Fumiko Yamamotoe Nippon Boehringer Ingelheim Co., Ltd, Tokyo, JapanCorrespondence[email protected]
View further author information
,
Søren S. Lundf Boehringer Ingelheim International GmbH, Ingelheim, GermanyView further author information
,
Tomoo Okamurae Nippon Boehringer Ingelheim Co., Ltd, Tokyo, JapanView further author information
&
Takashi Kadowakig President, Toranomon Hospital, Tokyo, JapanCorrespondence[email protected]
View further author information
Pages 1303-1313 | Received 01 Dec 2021, Accepted 22 Mar 2022, Published online: 03 May 2022

References

  • International Diabetes Federation. IDF diabetes atlas. Belgium: International Diabetes Federation; 2019. [cited 2022 Apr 5]. Available from: https://www.diabetesatlas.org/en/resources/.
  • Ministry of Health, Labour, and Welfare, Japan. National Health and Nutrition Survey. 2016. [cited 2022 Apr 5]. Available from: https://www.mhlw.go.jp/english/
  • Araki E, Goto A, Kondo T, et al., Japanese clinical practice guideline for diabetes 2019. J Diabetes Investig. 11(4): 1020–1076. 2020.
  • Yabe D, Higashiyama H, Kadowaki T, et al., Real-world observational study on patient outcomes in diabetes (RESPOND): study design and baseline characteristics of patients with type 2 diabetes newly initiating oral antidiabetic drug monotherapy in Japan. BMJ Open Diabetes Res Care. 8(2): e001361. 2020.
  • Deeks ED. Linagliptin: a review of its use in the management of type 2 diabetes mellitus. Drugs. 2012;72(13):1793–1824.
  • Barnett AH, Huisman H, Jones R, et al. Linagliptin for patients aged 70 years or older with type 2 diabetes inadequately controlled with common antidiabetes treatments: a randomised, double-blind, placebo-controlled trial. Lancet. 2013;382(9902):1413–1423.
  • Gallwitz B, Rosenstock J, Rauch T, et al. 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial. Lancet. 2012;380(9840):475–483.
  • Chan JC, Malik V, Jia W, et al. Diabetes in Asia: epidemiology, risk factors, and pathophysiology. JAMA. 2009;301(20):2129–2140.
  • Ma RC, Chan JC. Type 2 diabetes in East Asians: similarities and differences with populations in Europe and the United States. Ann N Y Acad Sci. 2013;1281(1):64–91.
  • Yoon KH, Lee JH, Kim JW, et al. Epidemic obesity and type 2 diabetes in Asia. Lancet. 2006;368(9548):1681–1688.
  • Yabe D, Seino Y, Fukushima M, et al. Beta cell dysfunction versus insulin resistance in the pathogenesis of type 2 diabetes in East Asians. Curr Diab Rep. 2015;15(6):602.
  • Kim YG, Hahn S, Oh TJ, et al. Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis. Diabetologia. 2013;56(4):696–708.
  • Takihata M, Nakamura A, Tajima K, et al. Comparative study of sitagliptin with pioglitazone in Japanese type 2 diabetic patients: the COMPASS randomized controlled trial. Diabetes Obes Metab. 2013;15(5):455–462.
  • Bae J, Song KH, Park JS, et al. Safety and effectiveness of linagliptin in Korean patients with type 2 diabetes: a postmarketing surveillance study. Diabetes Obes Metab. 2021;23(5):1208–1212.
  • Del Prato S, Patel S, Crowe S, et al. Efficacy and safety of linagliptin according to patient baseline characteristics: a pooled analysis of three phase 3 trials. Nutr Metab Cardiovasc Dis. 2016;26(10):886–892.
  • Ning G, Bandgar T, Hehnke U, et al., Efficacy and safety of linagliptin in 2681 Asian patients stratified by age, obesity, and renal function: a pooled analysis of randomized clinical trials. Adv Ther. 34(9): 2150–2162. 2017.
  • Yamamoto F, Unno Y, Okamura T, et al., Long-term safety and effectiveness of linagliptin in Japanese patients with type 2 diabetes mellitus: a 3-year post-marketing surveillance study. Diabetes Ther. 11(1): 107–117. 2020.
  • Yamamoto F, Ikeda R, Ochiai K, et al., Long-term safety and effectiveness of linagliptin in Japanese patients with type 2 diabetes and renal dysfunction: a post-marketing surveillance study. Diabetes Ther. 11(2): 523–533. 2020.
  • Chowdhury MZI, Turin TC. Variable selection strategies and its importance in clinical prediction modelling. Fam Med Community Health. 2020;8(1):e000262.
  • Aso Y, Ozeki N, Terasawa T, et al. Serum level of soluble CD26/dipeptidyl peptidase-4 (DPP-4) predicts the response to sitagliptin, a DPP-4 inhibitor, in patients with type 2 diabetes controlled inadequately by metformin and/or sulfonylurea. Transl Res. 2012;159(1):25–31.
  • Nomiyama T, Akehi Y, Takenoshita H, et al. Contributing factors related to efficacy of the dipeptidyl peptidase-4 inhibitor sitagliptin in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract. 2012;95(2):e27–28.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.